DIABETES MELLITUS-NEPHROPATHY MANAGEMENT
SUMMARY
ACE INHIBITORS/ANGIOTENSIN RECEPTOR BLOCKERS
1. Renoprotection in T2DM offered by ACEi & ARBs was demonstrated in RENAAL & IDNT studies.
2. These work by reducing intraglomerular pressure, by reducing efferent arteriolar tone.
SGLT2 INHIBITION
3. The CREDENCE study delay in progress in patients with established diabetic nephropathy who were treated with Canagliflozin[1].
Reference(s)
- ↑ Perkovic, V., de Zeeuw, D., Mahaffey, K., Fulcher, G., Erondu, N., Shaw, W., Barrett, T., Weidner-Wells, M., Deng, H., Matthews, D. and Neal, B., 2018. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. The Lancet Diabetes & Endocrinology, 6(9), pp.691-704.
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].
